As shown in Fig. 4A, B, levels of IFNγ and IL-2 for cells treated for 48 h, and in Fig. 4C for those treated for 72 h (IL-2), were much higher in the supernatants of the co-cultures of tumor cells and hPBMCs treated with all the novel tribodies compared to those observed in the combinatorial treatments of their 53 P control tribody with pembrolizumab, atezolizumab or relatlimab, respectively. This evidence concerns the gene IL2 and neoplasm.